{
  "id": 16882113,
  "title": "GSK shares slump as vaccine sales fall",
  "url": "https://urgent.news/2026/10/28/gsk-shares-slump-as-vaccine-sales-fall",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T10:01:21.000Z",
  "source": {
    "name": "City AM",
    "slug": "city-am",
    "url": "https://www.cityam.com/gsk-shares-slump-as-vaccine-sales-fall/"
  },
  "original_language": "en",
  "account": "GlaxoSmithKline (GSK) shares experienced a significant decline, marking the steepest drop since April, following the pharmaceutical company's announcement of a substantial decrease in vaccine sales. The FTSE 100 medicine leader witnessed a drop of up to five percent in early trading on Wednesday, as investors overlooked the group's higher-than-expected revenue. In the third quarter, GSK reported a turnover of £8.9 billion, which represented a five percent increase compared to the previous year and a one percent increase above analyst estimates. While specialty medicines, particularly injectable HIV medicines and oncology drugs, contributed to the growth in revenue, a two percent decline in vaccine revenue to £2.6 billion caused the pharma giant's performance to suffer. The vaccine sales drop was exacerbated by a 14 percent reduction in revenues for Arexvy, GSK's vaccine for respiratory tract diseases, which fell to £0.2 billion. This decline, combined with a 12 percent increase in meningitis vaccine sales, resulted in a net decrease in the company's overall revenue. Chris Beauchamp, chief market analyst at investment platform IG, pointed out that GSK's vaccine business woes \"suggest tougher trading in the coming quarters.\" Despite the initial share price dip, the stock returned to its October first-half gains, leaving GSK at a flat position for the year at £18.33. Analysts at Shore Capital, who maintain a 'buy' recommendation on the stock, stated that GSK has shed the reputation of being a perennial disappointment and is increasingly difficult to overlook given its progress since the CHC demerger. The stockbroker believes that GSK is making significant strides in its growth ambitions, particularly with the successful launches of new products. However, the company still needs to deliver positive news on its core products soon to avoid losing more of the 2025 share price gains. GSK CEO Luke Miels expressed that the company has delivered another strong quarter, with its key growth drivers and new launches performing well. Miels remains focused on operational delivery, execution, and accelerating research and development (R&D). In July, GSK announced significant job cuts as part of a plan to finance a new £400 million mega-campus in Cambridge, aiming to make it the company's new research and development hub, previously based in Stevenage.",
  "summary": "GSK shares have fallen the steepest since April, after the British pharmaceuticals giant reported a sharp drop in vaccine sales. The FTSE 100 medicines titan slumped up to five per cent in early trading on Wednesday, as investors looked past the group’s higher-than-expected revenue. The London-based group posted a £8.9bn turnover in the third quarter, [...]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}